Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 3/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.37 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21538693 | 0.90 | NQO2 (0.56) | NQO2MTNR1AMTNR1BHSD17B1PPARD | |
| SCHEMBL23934297 | 0.84 | NQO2 (0.47) | NQO2MTNR1AMTNR1BHSD17B1PPARD | |
| SCHEMBL12035547 | 0.83 | NQO2 (0.46) | NQO2MTNR1AMTNR1BHSD17B1PPARD | |
| SCHEMBL5861977 | 0.81 | NQO2 (0.43) | NQO2MTNR1AMTNR1BHSD17B1PPARD | |
| SCHEMBL821099 | 0.78 | PPARD (0.60) | NQO2MTNR1AMTNR1BPPARDPPARA | |
| SCHEMBL821443 | 0.78 | PPARD (0.60) | NQO2MTNR1AMTNR1BPPARDPPARA | |
| SCHEMBL1470331 | 0.78 | MTNR1A (0.60) | NQO2MTNR1AMTNR1B | |
| SCHEMBL12035617 | 0.78 | PPARD (0.60) | NQO2MTNR1AMTNR1BPPARDPPARA | |
| SCHEMBL10260558 | 0.76 | NQO2 (0.40) | NQO2MTNR1AMTNR1BHSD17B1PPARD | |
| SCHEMBL28348568 | 0.76 | CYP11B1 (0.42) | NQO2MTNR1AMTNR1BHSD17B1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109222-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | NQO2 1168/4885MTNR1A 327/4885MTNR1B 258/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | NQO2 1168/4885MTNR1A 327/4885MTNR1B 258/4885 |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | NQO2 1168/4885MTNR1A 327/4885MTNR1B 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.